NEA leads $50.5 mln Series C round in Trevi Therapeutics
New Enterprise Associates led a $50.5 million Series C funding round in late-stage clinical development company Trevi Therapeutics, Inc. Other investors in the funding round include Lundbeckfonden Ventures, Omega Funds and Aperture Venture Partners, along with the company's largest investor, TPG Biotech.
20 July 2017•3 mins read
